DNA methylation status at diagnosis in MDS predicts response to azacitidine
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci208317 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Qin Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry & Molecular Biology, and. Hauptthemen laut MEDLINE: DNA Methylation, Myelodysplastic Syndromes, Azacitidine, Epigenesis, Genetic. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, Blood Cancer United.
Abstract (Originalsprache)
Background
Myelodysplastic syndromes (MDS) are characterized by aberrant DNA methylation, and mutations in epigenetic modifiers are frequently found in these patients. Although DNA methyltransferase inhibitors (DNMTi) are used to treat MDS, response variability remains a challenge in the clinic, with limited predictive markers.
Methods
We integrated genomic, epigenomic, and transcriptomic analyses of 98 MDS patients. Patients were classified into epigenetic subtypes via hierarchical clustering. Random forest classifiers were developed and validated using internal stratified testing and an independent external cohort to predict AZA response.
Results
MDS is characterized by widespread DNA hypomethylation affecting distal regulatory elements. We identified seven epigenetic clusters correlated with distinct molecular drivers. Notably, Cluster VI exhibited low mutational burden but a high AZA response rate of 71% (P ≤ 0.01). While transcriptional profiles alone failed to distinguish responders, a DNAme-based classifier achieved an area under the curve (AUC) of 0.82. An integrative model combining DNAme, gene expression, mutations, and clinical parameters achieved an AUC of 0.93 in internal validation and 0.88 in the external cohort.
Conclusion
Epigenetic signatures at distal genomic elements provide superior predictive power for AZA response compared to promoter-centric or transcriptional analyses. These findings establish a robust framework for personalized treatment strategies in MDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry & Molecular Biology, and.
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
- MDS Unit, Hematology, DMSC University of Florence, AOU Careggi, Florence, Italy.
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland, USA.
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- Blood Cancer United
- NHLBI
Zitieren
APA
Yang, Q., Torres-Martin, M., Taguchi, M., Brogi, A., Casalin, I., Ceneri, E., Halene, S., DeZern, A. E., Griffiths, E. A., Follo, M. Y., Finelli, C., Radich, J. P., Rauh, M. J., Bejar, R., Sekeres, M. A., Santini, V., & Figueroa, M. E. (2026). DNA methylation status at diagnosis in MDS predicts response to azacitidine. Journal of Clinical Investigation. https://doi.org/10.1172/jci208317
Vancouver
Yang Q, Torres-Martin M, Taguchi M, Brogi A, Casalin I, Ceneri E, et al. DNA methylation status at diagnosis in MDS predicts response to azacitidine. Journal of Clinical Investigation. 2026. doi:10.1172/jci208317
BibTeX
@article{Yang2026,
author = {Yang, Qin and Torres-Martin, Miguel and Taguchi, Masataka and Brogi, Alice and Casalin, Irene and Ceneri, Eleonora and Halene, Stephanie and DeZern, Amy E and Griffiths, Elizabeth A and Follo, Matilde Y and Finelli, Carlo and Radich, Jerald P and Rauh, Michael J and Bejar, Rafael and Sekeres, Mikkael A and Santini, Valeria and Figueroa, Maria E},
title = {DNA methylation status at diagnosis in MDS predicts response to azacitidine},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci208317}
}
EUVIMED